The publication titled “Public subsidies for R&D and public sector drug development” has been cited by the European Parliament, as well as by the World Health Organization.
The publication titled “Revisiting the Relationship Between Price Regulation and Pharmaceutical R&D Investment” has been cited by the British Department of Health regarding the proposed changes to the statutory scheme to control the costs of branded health service medicines.